Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.59 |
| ▸ | CCND1 | P24385 | 4/20 | 0.59 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571527 | 0.73 | CDK4 (0.81) | CDK4CCND1P2RX7LMNAABCB1 | |
| SCHEMBL2410943 | 0.73 | CDK4 (0.81) | CDK4CCND1P2RX7LMNAABCB1 | |
| SCHEMBL7817628 | 0.73 | CDK4 (0.69) | CDK4CCND1LMNADRD2DRD4 | |
| SCHEMBL9702210 | 0.71 | CDK4 (0.82) | CDK4CCND1P2RX7LMNAABCB1 | |
| SCHEMBL6396944 | 0.71 | CDK4 (0.82) | CDK4CCND1P2RX7LMNAABCB1 | |
| SCHEMBL2357919 | 0.71 | CDK4 (0.78) | CDK4CCND1P2RX7LMNAABCB1 | |
| SCHEMBL20582233 | 0.70 | CDK4 (0.59) | CDK4CCND1 | |
| SCHEMBL2458779 | 0.70 | TDP1 (0.55) | LMNAHTR2A | |
| SCHEMBL11366447 | 0.70 | CDK4 (1.00) | CDK4CCND1LMNAMTNR1AMTNR1B | |
| SCHEMBL8656866 | 0.70 | CDK4 (0.81) | CDK4CCND1P2RX7LMNAABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237595-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2011-09-29 | — | — | US | disclosed |
| EP-2251324-A1 | HETEROARYL-ALKYLCARBAMATE COMPOUNDS AND THEIR USE AS INHIBITORS OF THE FAAH ENZYME | Sanofi-Aventis (FR) | 2010-11-17 | — | — | EP | disclosed |
| US-20100069405-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2010-03-18 | — | — | US | disclosed |
| US-7645757-B2 | Derivatives of heteroaryl-alkylcarbamates, methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors | SANOFI-AVENTIS (FR) | 2010-01-12 | — | — | US | disclosed |
| EP-1720829-B1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-10-14 | — | — | EP | disclosed |
| US-20070021426-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| EP-1720829-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | Sanofi-Aventis (FR) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005090292-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237595-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR1 | CDK4 1539/4885CCND1 1522/4885P2RX7 141/4885 |
| US-20100069405-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR1 | CDK4 1539/4885CCND1 1522/4885P2RX7 141/4885 |
| US-20070021426-A1 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | CDK4 1792/4885CCND1 2935/4885P2RX7 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.